Capped mesoporous silicates
View Patent ↗The invention provides an article comprising, a mesoporous silicate matrix, such as a particle, having one or more pores; and one or more releasable caps obstructing one or more of the pores. The articles are useful as delivery vehicles for encapsulated agents such as therapeutic agents, polynucleotides, polypeptides and the like.
1. A particle comprising an approximately spherical mesoporous silicate body having a multiplicity of pores, and one or more removable caps obstructing one or more of the pores;
wherein the mesoporous silicate body has a particle size of less than about 750 nm and the pores of the mesoporous silicate body have a diameter of less than about 50 nm;
wherein the one or more caps comprise an organic polymer covalently bonded to the mesoporous silicate body through a linking group of formula X—CH 2 CH 2 CH 2 SSCH 2 CH 2 NHC(═O)CH 2 —Y, wherein X is a silicon atom of the mesoporous silicate and Y is an atom of the organic polymer.
2. The particle of claim 1 wherein the pores are about 1-50 nm in diameter.
3. The particle of claim 1 wherein the pores are less than about 40 nm in diameter.
4. The particle of claim 1 wherein the pores are less than about 30 nm in diameter.
5. The particle of claim 1 wherein the pore wall thickness of the particle is about 18 angstroms to about 23 angstroms.
6. The particle of claim 1 wherein the organic polymer is a dendrimer, a biopolymer, or a polymeric nanosphere.
7. The particle of claim 6 wherein the dendrimer is a cationic dendrimer or an anionic dendrimer.
8. The particle of claim 6 wherein the dendrimer is a biodegradable poly(amidoamine) dendrimer.
9. The particle of claim 6 wherein the organic polymer is a biopolymer and the biopolymer is a protein, a polypeptide, an oligonucleotide, or an oligosaccharide.
10. The particle of claim 6 wherein the organic polymer is poly(lactic acid).
11. The particle of claim 1 wherein the particle is spherical.
12. The particle of claim 1 further comprising an encapsulated agent enclosed in one or more of the pores.
13. The particle of claim 12 wherein the encapsulated agent is a bioactive agent, a therapeutic agent, or a diagnostic agent.
14. The particle of claim 13 wherein the encapsulated agent is a chemotherapeutic agent, a chelated radionuclide, an immunosuppressive drug, an anti-inflammatory agent, an antibacterial agent, an antifungal agent, an antiviral agent, an analgesic agent, a polypeptide, a hormone, a hormonal messenger, a cytokine, an imaging agent, a contrast agent, an enzyme, a vitamin, a cosmetic agent, a nutrient, a gene expression suppressive drug, a neurotransmitter, a RNA molecule, or a DNA molecule.
15. A pharmaceutical composition comprising a particle as described in claim 13 and a pharmaceutically acceptable carrier.
16. The composition of claim 15 which is formulated for oral administration, for topical administration, or for administration by injection.
17. The particle of claim 1 wherein the mesoporous silicate body is a sphere having a diameter of less than about 300 nm.
18. The particle of claim 1 wherein the mesoporous silicate body is a sphere having a diameter of less than about 100 nm.
19. The particle of claim 1 wherein the mesoporous silicate body has a surface area of about 600 m 2 /g to about 1,100 m 2 /g.
20. The particle of claim 1 wherein the mesoporous silicate body has a loading capacity for encapsulated agents equivalent to more than 18 μmol per 100 mg of particles.
21. The particle of claim 1 wherein the mesopore volume of the particle is about 0.4 cm 3 /g to about 0.8 cm 3 /g.
22. The particle of claim 1 wherein the surface coverage of the one or more mercaptoalkyl, haloalkyl, aminoalkyl, carboxyalkyl, ureaalkyl, (carbamic acid)alkyl, cyanoalkyl, sulfonylalkyl, arylalkyl, alkynyl, or alkenyl groups on the particle is about 13% to about 33%.